Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) Net Income towards Common Stockholders (2020 - 2024)

Agilon Health (AGL) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 1419.51% year-over-year to $14.0 million, compared with a TTM value of $14.0 million through Dec 2025, up 235.37%, and an annual FY2025 reading of $14.0 million, up 242.51% over the prior year.
  • Net Income towards Common Stockholders was $14.0 million for Q4 2025 at Agilon Health, up from -$14.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $14.0 million in Q1 2025 and bottomed at -$67.6 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$5.4 million, with a median of -$769000.0 recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 13410.0% in 2023, then surged 1419.51% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$21.1 million in 2021, then surged by 97.64% to -$500000.0 in 2022, then tumbled by 13410.0% to -$67.6 million in 2023, then surged by 98.43% to -$1.1 million in 2024, then soared by 1419.51% to $14.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for AGL at $14.0 million in Q4 2025, -$14.0 million in Q2 2025, and $14.0 million in Q1 2025.